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Background: Interstitial deletions of 4q21 (MIM 613509) have already been reported in more than a dozen patients
with deletions ranging from 2 to 15.1 Mb delineating a common phenotype including marked growth restriction,
hypotonia, severe developmental delay with absent or delayed speech and distinctive facial features. A minimal
critical region of 1.37 Mb accounting for the common features with 5 known genes (PRKG2, RASGEF1B, HNRNPD,
HNRPDL, and ENOPH1) has been described so far.
Results: Here we report on a 5 year-old Hungarian girl presenting with severe developmental delay, good receptive
language but absent spoken speech, short stature, dystrophy, hypotonia, distinctive facies including broad forehead,
frontal bossing, downward slanting palpebral fissures, hypertelorism, hypoplastic ear-lobes, anteverted nostrils, short
philtrum, small mouth, higharched palate, short, small hands and feet, distally narrowing fingers and clinodactyly.
Cerebral MRI showed ventricular dilation and an increase in periventricular signal intensity. After extensive metabolic
tests and exclusion of subtelomeric deletions array CGH analysis was performed using the Agilent Human Genome G3
SurePrint 8x60K Microarray (Agilent Technologies, USA), which detected a 4,85 Mb de novo interstitial deletion of
4q21.21-4q21.23. The clinical symptoms only partly overlap with reported 4q21 microdeletion cases. Among multiple
annotated genes our patient is also haploinsufficient for the following genes: RASGEF1B being a strong candidate for
the neurodevelopmental features and PRKG2 for severe growth delay.
Conclusion: The first Hungarian case of 4q21 deletion adds to the phenotypic spectrum of this novel microdeletion
syndrome and underlines the importance of array CGH to uncover the heterogeneous causes of intellectual disability.
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The recent wide-spread use of microarray-based com-
parative genomic hybridization (array CGH) has exten-
sively aided the elucidation of the underlying cause in
patients with severe developmental delay and intellectual
disability with dysmorphic features [1]. Interstitial dele-
tions of 4q21 have been reported in about a dozen patients
[1-8] with deletions ranging from 2 to 15.1 Mb delineating
a common phenotype including marked growth restric-
tion, hypotonia, severe developmental delay with absent or* Correspondence: melegh.bela@pte.hu
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unless otherwise stated.delayed speech, small hands and feet and distinctive facial
features as broad forehead, hypertelorism, and prominent
central incisors. A minimal critical region of 1.37 Mb ac-
counting for the common features with 5 known genes
(PRKG2, RASGEF1B, HNRNPD, HNRPDL, ENOPH1) has
been described so far [5].
Here, we report the first Hungarian case of 4q21 dele-




After extensive metabolic tests and exclusion of subtelo-
meric deletions array CGH analysis was performed using
the Agilent Human Genome G3 SurePrint 8x60K Micro-
array, which detected a 4,85 Mb de novo interstitial de-
letion of 4q21.21-4q21.23 (ch4:81 408 980–86 261 953)l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lowing genes: PRKG2 (MIM 601591), RASGEF1B (MIM
614532), HNRNPD (MIM 607137), HNRPDL, ENOPH1,
COQ2, MRPS18C, THAP9, HPSE, and CDS1. Except for
known CNVs, no copy number alterations were ob-
served in other chromosomes (data not shown). Based
on the normal CGH array profile of the parents this de-
letion proved to be de novo. The deletion was not re-
ported as polymorphic or structural variant in the
publicly available databases.
Discussion
The widespread use of array CGH has led to the delinea-
tion of many novel entities associated with developmen-
tal delay [1]. Beyond revealing the underlying cause it
provides information for prognosis, the medical manage-
ment of the symptoms and access to resources for theFigure 1 Ensembl and aCGH image of the 4q21.21-q21.23 deletion. P
and the 4q21 microdeletion syndrome minimal critical region highlighted
breakpoints are clearly visible.affected families, and also gives the basis for estimating
recurrence risks.
Several reports and studies have delineated a 4q21
microdeletion syndrome with a common phenotype in-
cluding marked growth restriction, hypotonia, severe de-
velopmental delay with absent or delayed speech, small
hands and feet and distinctive facial features as broad
forehead, hypertelorism, and prominent lower and upper
incisors [5]. A minimal critical region of 1.37 Mb with 5
known genes (PRKG2, RASGEF1B, HNRNPD, HNRPDL,
ENOPH1) has been described so far [5]. Comparison of
our case with previously published cases (Table 1) re-
vealed several common features but also some variation
in the phenotype. The 4.85 Mb deletion in our patient
includes the minimal critical region of the 4q21 micro-
deletion syndrome, encompassing the candidate genes,
PRKG2 and RASGEF1B, previously described as majorart A is the Ensembl image of the deleted area with the affected genes
[9]. Part B is our aCGH image where the 4.85 Mb deletion and its exact
Table 1 Phenotypic differences between patients with 4q21 microdeletions and common features of the minimal
critical region







Deletion 4q21.21-21.22 4q21.22-q21.23 4q21.21-q22.3 4q21.21-4q21.23
Size (Mb) 1.37 2.0 15.1 4.85
Age at diagnosis (years) NA 7 8 5
Craniofacial features
Frontal bossing, broad forehead Yes Yes Yes Yes
Downslanting palpebral fissures ND Yes ND Yes
Hypertelorism Yes Yes No Yes
Anteverted nostrils ND ND Yes Yes
Short philtrum ND ND Yes Yes
Hypoplastic ear-lobes ND No Yes Yes
Small mouth ND Yes ND Yes
Higharched palate ND Yes ND Yes
Developmental delay Yes Moderate Yes Yes
Neonatal hypotonia Yes No Yes Yes
Gross motor delay Yes moderate Yes Yes
Delayed speech Yes Yes Yes Yes
Stereotypic movements ND ND ND Yes
Behavioral disturbance ND Yes ND Yes
Anthropometric and skeletal abnormalities Yes Yes Yes Yes
IUGR ND No Yes Yes
Birth weight (centile) ND 50th 25th 25-50th
Postnatal growth delay Yes No −5SD −2SD
Conserved head circumference Yes +1SD −0.5SD +1 SD
Small hands and small feet Yes Yes No Yes
Brachydactyly Yes Yes No Yes
Cerebral imaging abnormality Yes Yes
Ventricular dilation ND No Yes Yes
Corpus callosum hypoplasia ND No ND Yes
Cerebellar vermis hypoplasia ND No ND No
Frontal cerebral hypoplasia ND No Yes No
Yes: feature present; no: feature absent; ND: data not accessible, NA: not applicable.
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haploinsufficiency with the patient portrayed as having
the smallest reported deletion in this region, a novel
2.0 Mb deletion encompassing three of the genes in the
proposed minimal critical region: HNRNPD, HNRPDL,
and ENOPH1 [7]. The shared features between this pa-
tient and our patient, including macrocephaly, small
hands and feet, developmental delay, and the distinctive
facial features of broad forehead, hypertelorism and
prominent lower incisors, stress the role of these genes
as likely candidates for the shared phenotype through
yet unrevealed mechanisms [7].Among the dysmorphic features the characteristic bra-
chydactyly observed in other patients was less pro-
nounced in our index patient, and no shorter 2nd toe
was observed as described in the classic phenotype. Joint
laxity and hypermobile joints, also observed in our pa-
tient, have been described recently in a patient with a
proximal 4q interstitial deletion of 24.89 Mb encompass-
ing 4q12–4q21.21 [10] and is only known in 3 additional
patients with proximal 4q deletions. In addition to the
common neurocognitive characteristics seen in most
4q21 cases our patient also exhibited stereotypic move-
ments and a behavioral disturbance including occasional
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described in the patient with the 2 Mb deletion [7]. It is
also noteworthy that good receptive language and com-
munication by sign was observed in our patient besides
absent speech also resembling the described case with a
large proximal 4q deletion [10], however, more studies
with the precise description of the deletion boundaries
will be needed to point out genes responsible for the
overlapping features.
The 4,85 Mb region involved in the deletion contains
a number of genes, some of which have already been
discussed as being major determinants of the phenotype
[1,5], while the role of other genes and their impact on
the phenotype still need to be elucidated. We have
learned from previous works that haploinsufficiency of
the minimal critical region is essential for the expression
of the classic 4q21 phenotype, within this region, the
genes PRKG2 and RASGEF1B, have been identified as
major determinants in the development of the character-
istic features [5]. RASGEF1B encodes a highly conserved
guanine nucleotide exchange factor for Ras family pro-
teins. This protein superfamily is involved in various
basic cellular functions such as signal transduction, cyto-
skeleton dynamics and intracellular trafficking. It is
highly expressed in the central nervous system, and may
play a role in actin and microtubule dynamics regulating
both dendrite and spine structural plasticity [11]. Since
several genes related to intellectual disability have been
identified in the Rho-GTPase signaling pathway, RAS-
GEF1B seems to play a role in the cognitive features of
the 4q21 phenotype [5].
There is strong evidence that the second basic feature
of the microdeletion syndrome, severe growth delay, can
be attributed to the PRKG2 gene which encodes a
cGMP-dependent protein kinase type II protein. Mice
with a null mutation of this gene developed postnatal
dwarfism as a result of severe endochondral ossification
defect at the growth plates and impaired chondrocyte
growth. While small hands, short fingers and feet were
described, no postnatal growth delay was observed in
the patient with the smallest described deletion [7] not
containing the PRKG2 gene, while in patients deleted for
the minimal critical region and in our current case
growth delay was severe (Table 1). Those observations
also underline that the haploinsufficiency of the PRKG2
gene could explain growth failure [7] in most of the
4q21 patients. On the other hand, haploinsufficiency of
PRKG2 has previously also been linked to severe cogni-
tive developmental delay [12].
Additionally the deletion in our patient also involved
several genes (BMP3, COQ2, MRPS18C, THAP9, HPSE,
and CDS1) for which no direct function can be linked to
the features observed in our patient. In rat embryos,
Bmp3 was suggested to be involved in pattern formationduring early skeletal development [13]. In Bmp3 −/−
embryos or newborns no skeletal defects were found,
only increased trabecular metaphyseal bone density and
total trabecular bone volume [14]. On the other hand, a
missense mutation in the BMP3 gene (F452L) was asso-
ciated with cranioskeletal differences in canines [15].
Strehle et al. argued that haploinsufficiency of BMP3
might be associated with short stature and other skeletal
anomalies in 4q21 interstitial deletions [16]. Thus, it
cannot be ruled out that haploinsufficiency of BMP3
may also contribute to the cranial features observed in
our patient, such as broad forehead and frontal bossing.
The HPSE gene encodes a heparanase belonging to the
family of endoglycosidases which cleave the heparan sul-
fate side chain of heparan sulfate proteoglycans (HSPGs)
and contribute to the remodeling of the extracellular
matrix for cell movement or the release of bioactive
molecules from the extracellular matrix or cell surface
[17]. Vlodavsky et al. demonstrated a correlation of
HPSE expression and heparanase activity with increased
metastatic potential in breast cancer tissues and cell
lines [18]. Currently no direct function of the HPSE gene
can be linked to developmental disorders, however, it
can be assumed that the basic function of extracellular
matrix remodeling might also be essential for neurode-
velopment. Further detailed case reports or experimental
data are needed to learn more about the clinical rele-
vance of those genes.
Conclusions
We describe the first Hungarian patient with a de novo
previously unreported interstitial 4q deletion, syndromic
severe developmental delay, absence of spoken language
and behavioral disturbance. The clinical symptoms in
our patient partially overlap with reported 4q21 micro-
deletion cases. Among the multiple annotated genes our
patient is also haploinsufficient for RASGEF1B, a strong
candidate for the neurodevelopmental features and
PRKG2 for severe growth delay. In the future elucidation
of the clinical relevance of several other deleted genes in
4q21 patients may help establish guidelines for adequate
healthcare management of those patients. Our case of
4q21 deletion adds to the phenotypic spectrum of this
novel microdeletion syndrome and underlines the im-
portance of array CGH to uncover the heterogeneous
causes of intellectual disability.
Methods
Patient report
The patient was a 5 year old girl born by caesarean sec-
tion at 39th week of gestation as the second child of
non-consanguineous healthy Hungarian parents, the
family history was unremarkable. Her birth weight was
2750 g (25–50 pc), her length 49 cm (5–10 pc), the head
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Apgar scores were 9/10. In the perinatal period mild ic-
terus, joint laxity in the hips, axial hypotonia and poor
feeding was noted. At 1 week of age severe axial hypo-
tonia and spasticity in the lower limbs was recognized
and there was only slight improvement following exten-
sive neurohabilitation. After 3 months her somatic and
psychomotor development slowed down and has been
very slow ever since. At 6 months of age the patient was
hospitalized with severe obstructive bronchitis and dur-
ing her first year she suffered several upper airway infec-
tions with dense mucous and chronic diarrhea, but
CFTR-related diseases were excluded. At 14 months of
age brain MRI revealed significantly widened and abnor-
mally structured ventricles, diminished periventricular
white matter and hypoplasia of the corpus callosum. At
the age of 18 month the patient was referred to our gen-
etic counseling unit because of severe hypotonia and de-
velopmental delay. Postnatal growth delay: weight was
9.5 kg (5–10 pc), height 68 cm (<3 pc) and head circum-
ference 48.5 cm (+1 SD) and a distinctive facies includ-
ing broad forehead, frontal bossing, downward slanting
palpebral fissures, hypertelorism, hypoplastic ear-lobes,
anteverted nostrils, short philtrum, small mouth, high-
arched palate as well as short, small hands and feet, dis-
tally narrowing fingers, clinodactyly and joint laxity were
noted. Neurological examination revealed severe gener-
alized hypotonia and absent speech development. Gross
motor milestones were severely delayed despite of exten-
sive neurohabilitation: at the age of 2.5 years she was un-
able to sit alone, she did not crawl and was unable to
stand alone. At the age of 5 years she was able to walk,
sit alone, but had no speech. She had good receptive lan-
guage and used signs and gestures to communicate but
had no speech. Stereotypical movements such as hand
clapping and flapping and a behavioral disturbance, in-
cluding occasional self-injurious behavior and aggression
toward others were observed. Epilepsy has not been
noted so far and repeated EEGs gave negative results.
Extensive metabolic (carnitine-ester profiling, amino
acids, urine organic acids, isoelectric focusing for CDGs)
and genetic testing (routine karyotyping, CFTR sequen-
cing, mitochondrial mutation screening) yielded negative
results.Array Comparative Genomic Hybridization (aCGH)
analysis
Array CGH was performed using the Agilent Human
Genome G3 SurePrint 8x60K Microarray (Agilent Tech-
nologies, USA), a high resolution 60-mer oligonucleotide
based microarray containing 55.077 60-mer probes, span-
ning coding and non-coding genomic sequences with me-
dian spacing of 33 kb and 41 kb, respectively.Purification of the DNA from blood was performed
using the DNA Purification Kit NucleoSpin®Dx Blood
(Macherey-Nagel, Germany) according to the manufac-
turer’s protocol. Concentration and purity of the extracted
DNA were measured with the NanoDrop spectrophotom-
eter (NanoDrop Technologies, Inc.). Pooled genomic
DNA from peripheral blood leukocytes of phenotypically
normal males or females from Promega was used as a ref-
erence (Promega Male/Female Reference DNA, Promega
Corporation, USA).
Labeling and hybridization were carried out based on
the Agilent protocol (Agilent Oligonucleotide Array-Based
CGH for Genomic DNA Analysis – Enzymatic Labeling
Protocol v7.2; July 2012). Array image was acquired using
an Agilent laser scanner G2565CA (Agilent Technologies,
California, USA) and analyzed with the Agilent Feature
Extraction software (v10.10.1.1.). Results were presented
by Agilent Cytogenomics software (v2.5.8.11). DNA se-
quence information refers to the public UCSC database
(Human Genome Browser, Feb 2009 Assembly; GRCh37:
hg19).
The deletion detected was aligned to known aberra-
tions listed in publicly available databases, such as the
DECIPHER (Database of Chromosomal Imbalance and
Phenotype in Humans using Ensembl Resources) [19],
DGV (the Database of Genomic Variants) [20], Ensembl
[21] and ECARUCA [22]. Parental samples were ana-
lyzed using the same array and method.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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